$781 Million is the total value of Logos Global Management LP's 46 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 75.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $58,472,000 | -1.7% | 1,173,188 | -8.3% | 7.48% | -37.1% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $20,309,000 | -20.5% | 721,454 | -22.1% | 2.60% | -49.1% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $17,796,000 | -31.6% | 1,200,000 | -40.0% | 2.28% | -56.2% |
| CYTK | Sell | CYTOKINETICS INC | $16,238,000 | -13.9% | 750,000 | -6.2% | 2.08% | -44.9% |
| AKUS | Sell | AKOUOS INC | $7,090,000 | -30.0% | 310,000 | -31.1% | 0.91% | -55.2% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $3,777,000 | -44.5% | 300,000 | -46.7% | 0.48% | -64.5% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $3,097,000 | -78.7% | 136,715 | -70.0% | 0.40% | -86.4% |
| RAPT | Sell | RAPT THERAPEUTICS INC | $1,001,000 | -77.7% | 31,100 | -79.9% | 0.13% | -85.8% |
| APLT | Exit | APPLIED THERAPEUTICS INC | $0 | – | -12,600 | -100.0% | -0.09% | – |
| MREO | Exit | MEREO BIOPHARMA GROUP PLCads | $0 | – | -200,000 | -100.0% | -0.12% | – |
| LUMO | Exit | LUMOS PHARMA INC | $0 | – | -50,000 | -100.0% | -0.16% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -158,484 | -100.0% | -0.30% | – |
| FUSN | Exit | FUSION PHARMACEUTICALS INC | $0 | – | -121,128 | -100.0% | -0.42% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -361,945 | -100.0% | -0.56% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -150,000 | -100.0% | -0.63% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -900,000 | -100.0% | -0.92% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -110,000 | -100.0% | -0.92% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -750,000 | -100.0% | -0.95% | – | |
| ETNB | Exit | 89BIO INC | $0 | – | -290,000 | -100.0% | -1.16% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -600,000 | -100.0% | -1.23% | – |
| IGMS | Exit | IGM BIOSCIENCES INC | $0 | – | -91,841 | -100.0% | -1.34% | – |
| GBIO | Exit | GENERATION BIO CO | $0 | – | -325,000 | -100.0% | -1.36% | – |
| OBSV | Exit | OBSEVA SA | $0 | – | -1,165,000 | -100.0% | -1.37% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -410,000 | -100.0% | -1.50% | – |
| PRNB | Exit | PRINCIPIA BIOPHARMA INC | $0 | – | -150,000 | -100.0% | -1.79% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -400,000 | -100.0% | -2.16% | – |
| PCVX | Exit | VAXCYTE INC | $0 | – | -455,000 | -100.0% | -2.87% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -625,000 | -100.0% | -3.04% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -1,200,000 | -100.0% | -3.26% | – |
| AMTI | Exit | APPLIED MOLECULAR TRANS INC | $0 | – | -664,186 | -100.0% | -3.34% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -268,500 | -100.0% | -3.38% | – |
| BNTX | Exit | BIONTECH SEsponsored ads | $0 | – | -295,000 | -100.0% | -3.93% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -200,000 | -100.0% | -6.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-11-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.